This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
by Zacks Equity Research
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
AZNNegative Net Change GSKNegative Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
by Zacks Equity Research
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
BMYNegative Net Change CYTKNegative Net Change CRMDNegative Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
by Zacks Equity Research
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
CRMDNegative Net Change EDITNegative Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
by Zacks Equity Research
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
NVSNegative Net Change RHHBYNegative Net Change ARWRNo Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Sep 3, 2025
by Zacks Equity Research
Companies In The News Are: SIG, PEP, CYTK, AL.
PEPNegative Net Change SIGNegative Net Change ALNegative Net Change CYTKNegative Net Change
biotechs consumer-staples retail transportation
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
by Sundeep Ganoria
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
by Ahan Chakraborty
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
RHHBYNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ABTPositive Net Change AMGNNegative Net Change MDTNegative Net Change SYKNegative Net Change DXCMPositive Net Change ABBVNegative Net Change
biotechnology biotechs healthcare medical medical-devices robotics
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
by Zacks Equity Research
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
ALNYNegative Net Change RHHBYNegative Net Change CRMDNegative Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
BIIBNegative Net Change LLYNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs medical pharmaceuticals
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
by Zacks Equity Research
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
JAZZNegative Net Change ACADNegative Net Change AXSMNegative Net Change
biotechs
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
by Zacks Equity Research
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
JNJNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs medical pharmaceuticals
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
by Zacks Equity Research
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
CRMDNegative Net Change KNSAPositive Net Change OTLKNegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
by Kanishka Das
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
VRTXNegative Net Change BEAMNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs
FDA Approves Updated COVID-19 Vaccines but With Restrictions
by Zacks Equity Research
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna vaccines
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
by Ahan Chakraborty
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
ALNYNegative Net Change PFENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
by Zacks Equity Research
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
INONegative Net Change CRMDNegative Net Change KNSAPositive Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
by Sundeep Ganoria
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
VRTXNegative Net Change BEAMNegative Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy medical pharmaceuticals
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
by Zacks Equity Research
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
by Ahan Chakraborty
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
by Zacks Equity Research
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
REGNNegative Net Change LLYNegative Net Change IMRXPositive Net Change
biotechs
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
by Zacks Equity Research
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
CPRXNegative Net Change CRMDNegative Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals